Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de eficacia y seguridad de DFL24498 en el tratamiento de AKC

16 de septiembre de 2026 actualizado por: Dompé Farmaceutici S.p.A

A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Participants With Atopic Keratoconjunctivitis (AKC)

This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. The study consists of 2 cohorts: the adult cohort includes approximately 138 participants and the pediatric cohort which includes approximately 15 participants. The cohorts will be randomized separately. Adult participants will be randomized in a 1:1 ratio, while pediatric participants will be randomized in a 2:1 ratio to receive DFL24498 or vehicle.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

The study will consist of 3 periods:

  1. Washout period (from Day -7 ± 1 to Day 1),
  2. Treatment Period (from randomization through Week12) and
  3. Follow-up period (Weeks 13 to 16).

Tipo de estudio

Intervencionista

Inscripción (Estimado)

153

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)
  • Número de teléfono: +39 02 583 831

Ubicaciones de estudio

      • Córdoba, España, 14012
        • Reclutamiento
        • METAVISION ARRUZAFA S.L. (Hospital Arruzafa)
      • Santiago de Compostela, España, 15706
        • Reclutamiento
        • Miranza Galicia
      • Valencia, España, 46015
        • Reclutamiento
        • Fundación de Oftalmología Médica de la Comunitat Valenciana (FOM)
      • Valladolid, España, 47011
        • Reclutamiento
        • OBA - Universidad de Valladolid
      • Zaragoza, España, 50009
        • Reclutamiento
        • Hospital Universitario Miguel Servet
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32256
        • Reclutamiento
        • Bowden Eye Associates - Southside Location
      • Miami, Florida, Estados Unidos, 33136
        • Reclutamiento
        • University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute
    • Georgia
      • Morrow, Georgia, Estados Unidos, 30260
        • Reclutamiento
        • Clayton Eye Clinical Research
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63131
        • Reclutamiento
        • Ophthalmology Associates
    • New York
      • New York, New York, Estados Unidos, 10017
        • Reclutamiento
        • NYU Langone Health - Eye Center
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Reclutamiento
        • Duke Eye Center - Ophthalmology
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38119
        • Reclutamiento
        • Total Eye Care, PA
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology
      • Bologna, Italia, 40138
        • Reclutamiento
        • IRCCS AOU di Bologna - Policlinico Sant'Orsola UO Oftalmologia
      • Chieti, Italia, 66100
        • Reclutamiento
        • Ospedale SS Annunziata, ASL 2 Lanciano Vasto Chieti
      • Florence, Italia, 50134
        • Reclutamiento
        • Azienda Ospedaliero Universitaria Careggi
      • Roma, Italia, 00161
        • Reclutamiento
        • AOU Policlinico Umberto I
      • Roma, Italia, 00128
        • Reclutamiento
        • Fondazione Policlinico Universitario Campus Bio-Medico
      • Verona, Italia, 37134
        • Reclutamiento
        • Azienda Ospedaliera Universitaria Integrata Verona

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

10 años a 65 años (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Male or Female aged ≥ 10 and ≤ 65 years.

  2. Diagnosis of AKC in both eyes, including the presence or medical history of the following:

    1. other atopic condition (ie., atopic dermatitis, periocular eczema, asthma, allergic rhinitis), AND
    2. chronic allergic blepharoconjunctivitis and/or keratoconjunctivitis.
  3. Ocular itching of at least 50 as assessed by VAS scale.

  4. Corneal fluorescein staining assessed by modified Oxford scale of at least grade 1 AND a bulbar conjunctival hyperemia assessed by VBR 10 scale of at least 40 (range 0 to 100) in the same eye.

  5. A composite symptoms score (CSyS) ≥ 5 (sum of the severity scores graded 0 to 3 for each of the following: itching, tearing, ocular discomfort, photophobia, and mucous discharge score) (CSyS range of 0 to 15).

  6. If a woman of childbearing potential (WOCBP), must have a negative pregnancy test at both screening and baseline visit, and use an acceptable contraception method.

Exclusion Criteria:

Participants will be excluded if any of the following criteria apply:

  1. Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.
  2. Evidence of an active ocular infection in either eye.
  3. Intraocular inflammation defined as anterior chamber flare > 0 by Standardization of Uveitis Nomenclature (SUN) grading, in either eye.
  4. Known or suspected ocular malignancy (ocular surface, intraocular, ocular adnexa).
  5. Presence of cancer or any other systemic or unstable disease that may affect the ability to participate in the clinical study in the opinion of the investigator including basal cell carcinoma.
  6. Participants that are anatomically monocular.
  7. Systemic disease not stabilized within 1 month before the screening visit (eg, diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (eg, current systemic infections) or with a condition incompatible with the frequent assessment required by the study.

Note: Additional protocol defined Inclusion/Exclusion criteria apply

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: DFL24498

Participants will be administered with DFL24498 eye drops in both eyes.

DFL24498 will be instilled in each eye for 12 Weeks.

Rescue medication may be administered as required at the Investigator discretion.

Comparador de placebos: Vehicle

Participants will be administered with vehicle eye drops in both eyes.

Rescue medication may be administered as required at the Investigator discretion.

Vehicle eye drops without active drug will be instilled in each eye for 12 Weeks.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline at week 6 in ocular itching score assessed by visual analog scale (VAS).
Periodo de tiempo: Baseline and at Week 6

The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point.

Baseline and at Week 6

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline at week 6 in corneal epithelial fluorescein staining, scored by modified Oxford scale, in the study eye.
Periodo de tiempo: Baseline and at Week 6

Fluorescein will be applied to the inferior fornix of the palpebral conjunctiva of each eye. To avoid the phenomenon of quenching, staining will be assessed within 1 to 4 minutes from fluorescein instillation. Examination will be performed at the slit-lamp using blue (cobalt) light. Corneal fluorescein staining will be graded according to the modified Oxford scale (7-point scale: 0, 0.5. 1, 2, 3, 4, 5).

Baseline and at Week 6
Change from baseline at week 6 in bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100), in the study eye.
Periodo de tiempo: Baseline and at Week 6

Bulbar conjunctival redness will be assessed at the slit-lamp examination using white light prior to vital dye instillation and graded according to the VBR 10 scale.

Baseline and at Week 6
Change from baseline over time in ocular itching score assessed by VAS.
Periodo de tiempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in ocular symptoms of itching, tearing, discomfort, mucous discharge, and photophobia on a 4-point scale (0 to 3).
Periodo de tiempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Ocular symptoms are assessed using a 4-point severity scale ranging from 0 (none) to 3 (severe). Five ocular symptoms, itching, tearing, ocular discomfort (including burning, stinging, and foreign body sensation), mucous discharge, and photophobia are evaluated in the study eye. A composite symptom score is described in calculated at screening and Baseline by summing the individual symptom scores, resulting in a total score range of 0 to 15, with higher scores indicating greater symptom severity.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in corneal fluorescein staining (modified Oxford scale) in the study eye.
Periodo de tiempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Corneal fluorescein staining modified Oxford scale (0-5) as per corneal dot count in each eye.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in bulbar conjunctival hyperemia assessed by VBR 10 scale (0 to 100) in the study eye.
Periodo de tiempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100).

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in signs of tarsal papillary reaction, corneal neovascularization, cicatrizing conjunctivitis and blepharitis on a 4-point scale (0 to 3) in the study eye.
Periodo de tiempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Change in signs on a 4-point scale (0 to 3) in the study eye.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline at week 6 and 12 in the QoL scores assessed by the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ-S) (assessed in the adult cohort only)
Periodo de tiempo: Baseline and at Week 6 and Week 12.

Standardized Rhinoconjunctivitis QoL Questionnaire (RQLQ[S]) is a validated questionnaire that assesses QoL specifically in patients with rhinoconjunctivitis. There are 28 questions, which are categorized under 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Each question is scored on a 7-point scale from no impairment (score 0) to severe impairment (score 6).

Baseline and at Week 6 and Week 12.
Patient Global Impression of Change (PGIC) at week 6 and week 12 (assessed in the adult cohort only)
Periodo de tiempo: At week 6 and week 12.

PGIC is a short questionnaire used to assess how a participant perceives changes in their condition following treatment, on a scale ranging from 1 to 7.

At week 6 and week 12.
Number of Participants receiving rescue medication over time after week 6
Periodo de tiempo: Week 6 to Week 12

Participants who received rescued medication over time after week 6 (visit 4).

Week 6 to Week 12
Number of participants with treatment-emergent adverse events and serious adverse events (SAEs)
Periodo de tiempo: Up to Week 16

Any adverse events occurring or worsening after the first administration of investigational product is classified as "treatment-emergent" adverse events and does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

Up to Week 16
Change from baseline over time in best corrected distance visual acuity (BCDVA) in each eye.
Periodo de tiempo: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Best corrected visual acuity (BCDVA) is determined by careful refraction according to the standard protocol for refraction. BCDVA is measured by Early Treatment of Diabetic Retinopathy Study chart.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline at week 12 in corneal endothelial cell density in each eye (only at selected sites that have the required equipment).
Periodo de tiempo: Baseline and at week 12

Corneal central region endothelial cell density will be determined for each eye using specular microscopy and expressed as the number of cells/mm2 using the Cell Density readout provided by the software.

Baseline and at week 12
Change from baseline at week 12 in dilated fundus exam in each eye
Periodo de tiempo: Baseline and at week 12

After specular microscopy, mydriatic drops will be instilled in both eyes and once adequate dilation is achieved, a fundal exam shall be performed to examine the vitreous, retina, and optic nerve.

Baseline and at week 12
Change from baseline over time in intraocular pressure in each eye.
Periodo de tiempo: Baseline and at Week 6 and Week 12

IOP will be assessed by tonometry for each eye and will be measured in mmHg.

Baseline and at Week 6 and Week 12
Number of participants discontinued due to tolerability during the treatment period
Periodo de tiempo: Baseline to week 12

Treatment discontinuation rate due to tolerability.

Baseline to week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de diciembre de 2025

Finalización primaria (Estimado)

1 de marzo de 2027

Finalización del estudio (Estimado)

1 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

22 de diciembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

3 de febrero de 2026

Publicado por primera vez (Actual)

9 de febrero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ICY-AKC-301
  • 2025-522291-83-00 (Ctis)
  • 2025 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .